David Stamler, M.D. has over 25 years of experience in the pharmaceutical industry and has led three drug approvals for treatment of neurological disorders. He was appointed Chief Executive Officer of Alterity Therapeutics in January 2021 after having served as the Chief Medical Officer and Senior Vice President, Clinical Development since 2017. Prior to joining Alterity, Dr. Stamler was Vice President and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries from 2015 to 2017 after Teva acquired Auspex Pharmaceuticals, where he had served as the Chief Medical Officer since January 2011. While at Auspex/Teva, Dr. Stamler led the development and approval of deutetrabenazine for the treatment of Huntington’s disease, an Orphan disease, and tardive dyskinesia. Dr. Stamler received his M.D. and B.A. degrees from the University of Chicago.